首页 > 最新文献

Pharmacological Research - Modern Chinese Medicine最新文献

英文 中文
Identifying active substances of Huangqin Decoction regulating intestinal epithelial barrier dysfunction by mass spectrometry networking and multiscale models 通过质谱网络和多尺度模型鉴定黄芩汤调节肠上皮屏障功能障碍的活性物质
Pub Date : 2026-01-08 DOI: 10.1016/j.prmcm.2026.100755
Juntao Wang , Yeting Zhou , Xutao Ge , Miao Zhu , Baiping Ma , Zheng Li , Yi Wang

Introduction

Huangqin decoction (HQD) is a traditional Chinese medicine prescription recorded in the "Shang Han Lun", a decoction composed of huangqin, chishao, gancao and dazao, which has been widely used to relieve symptoms of gastrointestinal diseases, such as ulcerative colitis (UC) and typhoid fever. However, its active components is yet to be clarified.

Methods

The chemical composition of HQD was analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by network pharmacology prediction. A colonic cell line and mouse colonic organoid inflammation model were established to observe the effects of HQD and its components on inflammatory factor expression and intestinal barrier function. The efficacy of the aqueous fraction of HQD (HQD-far-A) was further validated in a zebrafish enteritis model by assessing intestinal oxidative stress levels, neutrophil aggregation levels, and goblet cell counts.

Results

In the Caco-2 cell inflammation model, HQD and its individual components all reduced the pharmacological effects of elevated inflammatory factors. Treatment with HQD-fra-A significantly protected the intestinal epithelial barrier, including tight junction proteins ZO-1 and Occludin, and this effect was validated in a DSS-induced intestinal organoid inflammation model. In vitro experiments demonstrated that HQD-fra-A reduced neutrophil aggregation and intestinal oxidative stress caused by intestinal inflammation in zebrafish, mitigated intestinal injury, and protected goblet cells to maintain the intestinal barrier.

Discussion

HQD has been validated as an effective treatment for colon inflammation by protecting the intestinal barrier. The multi-scale model for drug efficacy validation provides a solid foundation and new insights for advancing drug efficacy evaluations in future research.
黄芩汤(HQD)是《商汉论》中记载的一种中药处方,是一种由黄芩、赤芍、甘草和大藻组成的汤剂,广泛用于缓解溃疡性结肠炎(UC)和伤寒等胃肠道疾病的症状。然而,其有效成分尚不清楚。方法采用液相色谱-串联质谱法(LC-MS/MS)分析HQD的化学成分,并进行网络药理学预测。通过建立结肠细胞系和小鼠结肠类器官炎症模型,观察HQD及其组分对炎症因子表达和肠道屏障功能的影响。通过评估肠道氧化应激水平、中性粒细胞聚集水平和杯状细胞计数,在斑马鱼肠炎模型中进一步验证了HQD水相组分(HQD-far- a)的功效。结果在Caco-2细胞炎症模型中,HQD及其各组分均可降低炎性因子升高的药理作用。hqd - fa - a治疗可显著保护肠上皮屏障,包括紧密连接蛋白ZO-1和Occludin,这种效果在dss诱导的肠道类器官炎症模型中得到了验证。体外实验表明,hqd -fra可降低斑马鱼肠道炎症引起的中性粒细胞聚集和肠道氧化应激,减轻肠道损伤,保护杯状细胞,维持肠道屏障。hqd已被证实是一种有效的治疗结肠炎症的方法,可以保护肠道屏障。该多尺度药物疗效验证模型为进一步开展药物疗效评价研究提供了坚实的基础和新的思路。
{"title":"Identifying active substances of Huangqin Decoction regulating intestinal epithelial barrier dysfunction by mass spectrometry networking and multiscale models","authors":"Juntao Wang ,&nbsp;Yeting Zhou ,&nbsp;Xutao Ge ,&nbsp;Miao Zhu ,&nbsp;Baiping Ma ,&nbsp;Zheng Li ,&nbsp;Yi Wang","doi":"10.1016/j.prmcm.2026.100755","DOIUrl":"10.1016/j.prmcm.2026.100755","url":null,"abstract":"<div><h3>Introduction</h3><div>Huangqin decoction (HQD) is a traditional Chinese medicine prescription recorded in the \"Shang Han Lun\", a decoction composed of huangqin, chishao, gancao and dazao, which has been widely used to relieve symptoms of gastrointestinal diseases, such as ulcerative colitis (UC) and typhoid fever. However, its active components is yet to be clarified.</div></div><div><h3>Methods</h3><div>The chemical composition of HQD was analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by network pharmacology prediction. A colonic cell line and mouse colonic organoid inflammation model were established to observe the effects of HQD and its components on inflammatory factor expression and intestinal barrier function. The efficacy of the aqueous fraction of HQD (HQD-far-A) was further validated in a zebrafish enteritis model by assessing intestinal oxidative stress levels, neutrophil aggregation levels, and goblet cell counts.</div></div><div><h3>Results</h3><div>In the Caco-2 cell inflammation model, HQD and its individual components all reduced the pharmacological effects of elevated inflammatory factors. Treatment with HQD-fra-A significantly protected the intestinal epithelial barrier, including tight junction proteins ZO-1 and Occludin, and this effect was validated in a DSS-induced intestinal organoid inflammation model. In vitro experiments demonstrated that HQD-fra-A reduced neutrophil aggregation and intestinal oxidative stress caused by intestinal inflammation in zebrafish, mitigated intestinal injury, and protected goblet cells to maintain the intestinal barrier.</div></div><div><h3>Discussion</h3><div>HQD has been validated as an effective treatment for colon inflammation by protecting the intestinal barrier. The multi-scale model for drug efficacy validation provides a solid foundation and new insights for advancing drug efficacy evaluations in future research.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100755"},"PeriodicalIF":0.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research progress of traditional Chinese medicine syndrome differentiation in prevention and treatment of hepatic encephalopathy 肝性脑病中医辨证防治的研究进展
Pub Date : 2026-01-07 DOI: 10.1016/j.prmcm.2026.100756
Zidong Zhang , Haodong Bai , Jiao Zhou , Desen Ke , Qiuhong Wang , Haixue Kuang

Introduction

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome caused by liver dysfunction and metabolic disturbances, presenting with consciousness disorders, behavioral abnormalities, and coma. Despite advances in modern medicine, effective prevention and management remain challenging. Traditional Chinese medicine (TCM) has shown promise in HE treatment through individualized syndrome differentiation and holistic therapeutic strategies.

Methods

A comprehensive literature search was conducted in CNKI, Wanfang Data, PubMed, and Google Scholar for studies published from 2005 to 2025. Search terms included combinations of “hepatic encephalopathy,” “traditional Chinese medicine,” “syndrome differentiation,” and “mechanism of action.” After removing duplicates and screening titles, abstracts, and full texts, studies reporting TCM interventions, syndrome differentiation, or mechanisms of HE treatment were included.

Results

Analysis revealed that TCM syndrome differentiation for HE predominantly involves phlegm-dampness, fire-toxin, liver-kidney deficiency, and qi-yin deficiency. Core therapeutic strategies include TCM compound decoctions, Chinese herbal enemas, and acupuncture. These interventions demonstrate efficacy in improving neurological symptoms, reducing inflammation and oxidative stress, and modulating gut microbiota.

Discussion

TCM offers a holistic, multi-target, and multi-pathway approach for HE management. Syndrome differentiation provides a theoretical basis for personalized therapy, while recent mechanistic studies suggest TCM’s role in modulating the gut–liver–brain axis and neuroinflammation. Standardizing syndrome classifications and integrating multi-omics approaches may further enhance the precision and modernization of TCM-based HE therapies.
肝性脑病(HE)是一种由肝功能障碍和代谢紊乱引起的神经精神综合征,表现为意识障碍、行为异常和昏迷。尽管现代医学取得了进步,但有效的预防和管理仍然具有挑战性。中医通过个体化辨证和整体治疗策略在HE治疗中显示出前景。方法在中国知网、万方数据、PubMed、b谷歌Scholar等数据库中检索2005 ~ 2025年发表的文献。搜索词包括“肝性脑病”、“中医”、“辨证”和“作用机制”的组合。在删除重复并筛选标题、摘要和全文后,纳入了报道中医干预、辨证或HE治疗机制的研究。结果HE的中医辨证以痰湿、火毒、肝肾虚、气阴虚为主。核心治疗策略包括中药复方煎剂、中药灌肠和针灸。这些干预措施在改善神经系统症状、减少炎症和氧化应激以及调节肠道微生物群方面显示出疗效。中医为HE管理提供了一种整体的、多目标的、多途径的方法。辨证为个性化治疗提供了理论基础,而最近的机制研究表明中医在调节肠-肝-脑轴和神经炎症方面的作用。规范证候分类,整合多组学方法,可进一步提高中医治疗的精准性和现代化程度。
{"title":"Research progress of traditional Chinese medicine syndrome differentiation in prevention and treatment of hepatic encephalopathy","authors":"Zidong Zhang ,&nbsp;Haodong Bai ,&nbsp;Jiao Zhou ,&nbsp;Desen Ke ,&nbsp;Qiuhong Wang ,&nbsp;Haixue Kuang","doi":"10.1016/j.prmcm.2026.100756","DOIUrl":"10.1016/j.prmcm.2026.100756","url":null,"abstract":"<div><h3>Introduction</h3><div>Hepatic encephalopathy (HE) is a neuropsychiatric syndrome caused by liver dysfunction and metabolic disturbances, presenting with consciousness disorders, behavioral abnormalities, and coma. Despite advances in modern medicine, effective prevention and management remain challenging. Traditional Chinese medicine (TCM) has shown promise in HE treatment through individualized syndrome differentiation and holistic therapeutic strategies.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted in CNKI, Wanfang Data, PubMed, and Google Scholar for studies published from 2005 to 2025. Search terms included combinations of <em>“hepatic encephalopathy,” “traditional Chinese medicine,” “syndrome differentiation,”</em> and <em>“mechanism of action.”</em> After removing duplicates and screening titles, abstracts, and full texts, studies reporting TCM interventions, syndrome differentiation, or mechanisms of HE treatment were included.</div></div><div><h3>Results</h3><div>Analysis revealed that TCM syndrome differentiation for HE predominantly involves phlegm-dampness, fire-toxin, liver-kidney deficiency, and qi-yin deficiency. Core therapeutic strategies include TCM compound decoctions, Chinese herbal enemas, and acupuncture. These interventions demonstrate efficacy in improving neurological symptoms, reducing inflammation and oxidative stress, and modulating gut microbiota.</div></div><div><h3>Discussion</h3><div>TCM offers a holistic, multi-target, and multi-pathway approach for HE management. Syndrome differentiation provides a theoretical basis for personalized therapy, while recent mechanistic studies suggest TCM’s role in modulating the gut–liver–brain axis and neuroinflammation. Standardizing syndrome classifications and integrating multi-omics approaches may further enhance the precision and modernization of TCM-based HE therapies.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100756"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146187332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-proliferative activity of Delphinium denudatum wall. ex Hook.f. & Thomson on U251 MG Glioblastoma Cells 白玉飞燕壁的抗增殖活性。Hook.f交货。& Thomson研究U251 MG胶质母细胞瘤细胞
Pub Date : 2026-01-07 DOI: 10.1016/j.prmcm.2026.100753
Amit Man Joshi , Sagar Atri , Ram Adhar Yadav , Santosh Kumar Thakur , Mithilesh Sah , Sirjana Shrestha , Aftab Alam Shah , Mukesh Kumar Yadav

Background

Delphinium denudatum Wall. ex Hook.f. & Thomson (D. denudatum), a perennial herb from the Ranunculaceae family, contains diterpenoid alkaloids with reported bioactivities. While certain Delphinium species are utilized in Chinese folk medicine for analgesic effects, specific documentation for D. denudatum in traditional Chinese medicine is limited. This study evaluates the anti-proliferative effects of its methanolic root extract (DDE) on the U251 MG glioblastoma cell line.

Materials and methods

U251 MG cells were treated with various concentrations of DDE and assessed for viability using the Cell Counting Kit-8 (CCK-8) assay. Fluorouracil (50 µg/mL) served as the positive control. The percentage of inhibition and IC₅₀ values were calculated from dose–response curves to evaluate the cytotoxic potential of the extract.

Results

DDE demonstrated a dose-dependent inhibition of U251 MG cell proliferation, peaking at ∼60% inhibition at 50 µg/mL, with an IC₅₀ of 43.75 µg/mL. Higher concentrations exhibited reduced inhibition, suggesting a biphasic response. These findings indicate selective cytotoxicity and therapeutic promise of DDE in targeting glioblastoma cells.

Discussion

These findings provide preliminary evidence of DDE's cytotoxic potential against glioblastoma cells, supporting further exploration of its bioactive constituents, such as diterpenoid alkaloids, for anti-cancer applications.
背景珠光飞燕墙。Hook.f交货。汤姆逊(D. denudatum)是毛茛科的多年生草本植物,含有具有生物活性的二萜生物碱。虽然某些种类的飞燕草在中医中用于镇痛作用,但在中医中具体的文献是有限的。本研究评价了其甲醇根提取物(DDE)对U251 MG胶质母细胞瘤细胞系的抗增殖作用。材料和方法用不同浓度的DDE处理su251 MG细胞,使用细胞计数试剂盒-8 (CCK-8)法评估细胞活力。氟尿嘧啶50µg/mL作为阳性对照。从剂量响应曲线计算抑制百分比和IC₅0值,以评估提取物的细胞毒性潜力。结果dde显示出对U251 MG细胞增殖的剂量依赖性抑制,在50µg/mL时达到抑制约60%的峰值,IC₅0为43.75µg/mL。浓度越高,抑制作用越弱,提示双相反应。这些发现表明DDE靶向胶质母细胞瘤细胞的选择性细胞毒性和治疗前景。这些发现为DDE对胶质母细胞瘤细胞的细胞毒性潜力提供了初步证据,支持进一步探索其生物活性成分,如二萜生物碱,用于抗癌应用。
{"title":"Anti-proliferative activity of Delphinium denudatum wall. ex Hook.f. & Thomson on U251 MG Glioblastoma Cells","authors":"Amit Man Joshi ,&nbsp;Sagar Atri ,&nbsp;Ram Adhar Yadav ,&nbsp;Santosh Kumar Thakur ,&nbsp;Mithilesh Sah ,&nbsp;Sirjana Shrestha ,&nbsp;Aftab Alam Shah ,&nbsp;Mukesh Kumar Yadav","doi":"10.1016/j.prmcm.2026.100753","DOIUrl":"10.1016/j.prmcm.2026.100753","url":null,"abstract":"<div><h3>Background</h3><div><em>Delphinium denudatum</em> Wall. ex Hook.f. &amp; Thomson (<em>D. denudatum</em>), a perennial herb from the Ranunculaceae family, contains diterpenoid alkaloids with reported bioactivities. While certain <em>Delphinium</em> species are utilized in Chinese folk medicine for analgesic effects, specific documentation for <em>D. denudatum</em> in traditional Chinese medicine is limited. This study evaluates the anti-proliferative effects of its methanolic root extract (DDE) on the U251 MG glioblastoma cell line.</div></div><div><h3>Materials and methods</h3><div>U251 MG cells were treated with various concentrations of DDE and assessed for viability using the Cell Counting Kit-8 (CCK-8) assay. Fluorouracil (50 µg/mL) served as the positive control. The percentage of inhibition and IC₅₀ values were calculated from dose–response curves to evaluate the cytotoxic potential of the extract.</div></div><div><h3>Results</h3><div>DDE demonstrated a dose-dependent inhibition of U251 MG cell proliferation, peaking at ∼60% inhibition at 50 µg/mL, with an IC₅₀ of 43.75 µg/mL. Higher concentrations exhibited reduced inhibition, suggesting a biphasic response. These findings indicate selective cytotoxicity and therapeutic promise of DDE in targeting glioblastoma cells.</div></div><div><h3>Discussion</h3><div>These findings provide preliminary evidence of DDE's cytotoxic potential against glioblastoma cells, supporting further exploration of its bioactive constituents, such as diterpenoid alkaloids, for anti-cancer applications.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100753"},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phyllanthus amarus as a multifunctional medicinal herb: Bioactive compounds, mechanisms, and clinical perspectives 余甘菊作为一种多功能中药:生物活性化合物、作用机制及临床前景
Pub Date : 2026-01-06 DOI: 10.1016/j.prmcm.2026.100752
Md Asaduzzaman , Lutfun Nahar , Mohammad Shahangir Biswas , Munna Kumar Podder , Md Matiar Rahman

Introduction

Phyllanthus amarus Schumach. & Thonn., commonly known in Traditional Chinese Medicine (TCM as Yexiazhu (叶下珠, Yè xià zhū), is a widely used medicinal herb in Asian, African, and South American traditional systems. In TCM practice, Yexiazhu is traditionally prescribed for heat-clearing and detoxification, particularly in the management of liver-and kidney-related disorders, viral infections, and inflammatory conditions. Its rich phytochemical composition, including lignans, flavonoids, and tannins, has prompted increasing scientific interest in validating its traditional therapeutic applications.

Materials and methods

This review critically evaluates literature published between 1977 and 2025, encompassing classical TCM texts, ethnomedicinal reports, and peer-reviewed experimental studies. Major scientific databases were surveyed to collect data on phytochemical constituents, pharmacological activities, molecular mechanisms, toxicological profiles, and available clinical evidence related to P. amarus and Yexiazhu-based preparations.

Results

Pharmacological studies indicate that P. amarus exhibits hepatoprotective, antidiabetic, antimicrobial, antioxidant, antiviral, anti-inflammatory, and nephroprotective activities. These effects are primarily attributed to bioactive compounds such as phyllanthin, hypophyllanthin, geraniin, corilagin, and quercetin. Commonly used TCM preparations, including aqueous decoctions and granule formulations of Yexiazhu, demonstrate therapeutic potential through modulation of oxidative stress, inflammatory signaling pathways, viral replication, and metabolic regulation. Despite strong experimental support from in vitro and in vivo models, clinical findings remain limited, heterogeneous, and occasionally inconsistent, particularly for hepatitis B and metabolic disorders.

Discussion

Collectively, P. amarus (Yexiazhu) represents a multifunctional medicinal herb with substantial experimental evidence supporting its traditional use in TCM and other medical systems. However, challenges related to species differentiation, phytochemical standardization, formulation variability, and limited high-quality clinical trials restrict its translation into modern evidence-based medicine. Future research should focus on standardized Chinese preparations, mechanistic validation, and rigorously designed clinical studies to clarify its therapeutic efficacy and safety.
phyllanthus amarus Schumach。, Thonn。通常在中医中被称为叶仙竹,是一种在亚洲、非洲和南美传统系统中广泛使用的草药。在中医实践中,叶泻珠传统上用于清热解毒,特别是在治疗肝肾相关疾病、病毒感染和炎症方面。其丰富的植物化学成分,包括木脂素、类黄酮和单宁,已经引起了越来越多的科学兴趣,以验证其传统的治疗应用。材料和方法本综述对1977年至2025年间发表的文献进行了批判性评价,包括经典中医文献、民族医学报告和同行评议的实验研究。通过对主要科学数据库的调查,收集了与野泻草制剂相关的植物化学成分、药理活性、分子机制、毒理学特征和现有临床证据。结果药理学研究表明,毛茛具有保护肝脏、抗糖尿病、抗菌、抗氧化、抗病毒、抗炎和肾保护作用。这些作用主要归因于生物活性化合物,如叶黄素、茶黄素、天竺葵素、胶原蛋白和槲皮素。常用的中药制剂,包括叶泻珠水煎剂和颗粒制剂,通过调节氧化应激、炎症信号通路、病毒复制和代谢调节,显示出治疗潜力。尽管体外和体内模型强有力的实验支持,临床发现仍然有限,异质性,有时不一致,特别是对于乙型肝炎和代谢紊乱。总的来说,野夏竹代表了一种多功能草药,有大量的实验证据支持其在中医和其他医疗系统中的传统用途。然而,与物种分化、植物化学标准化、配方可变性和有限的高质量临床试验相关的挑战限制了其向现代循证医学的转化。未来的研究应侧重于标准化中药制剂、机制验证和严格设计的临床研究,以阐明其疗效和安全性。
{"title":"Phyllanthus amarus as a multifunctional medicinal herb: Bioactive compounds, mechanisms, and clinical perspectives","authors":"Md Asaduzzaman ,&nbsp;Lutfun Nahar ,&nbsp;Mohammad Shahangir Biswas ,&nbsp;Munna Kumar Podder ,&nbsp;Md Matiar Rahman","doi":"10.1016/j.prmcm.2026.100752","DOIUrl":"10.1016/j.prmcm.2026.100752","url":null,"abstract":"<div><h3>Introduction</h3><div><em>Phyllanthus amarus</em> Schumach. &amp; Thonn., commonly known in Traditional Chinese Medicine (TCM as Yexiazhu (叶下珠, Yè xià zhū), is a widely used medicinal herb in Asian, African, and South American traditional systems. In TCM practice, Yexiazhu is traditionally prescribed for heat-clearing and detoxification, particularly in the management of liver-and kidney-related disorders, viral infections, and inflammatory conditions. Its rich phytochemical composition, including lignans, flavonoids, and tannins, has prompted increasing scientific interest in validating its traditional therapeutic applications.</div></div><div><h3>Materials and methods</h3><div>This review critically evaluates literature published between 1977 and 2025, encompassing classical TCM texts, ethnomedicinal reports, and peer-reviewed experimental studies. Major scientific databases were surveyed to collect data on phytochemical constituents, pharmacological activities, molecular mechanisms, toxicological profiles, and available clinical evidence related to <em>P. amarus</em> and Yexiazhu-based preparations.</div></div><div><h3>Results</h3><div>Pharmacological studies indicate that <em>P. amarus</em> exhibits hepatoprotective, antidiabetic, antimicrobial, antioxidant, antiviral, anti-inflammatory, and nephroprotective activities. These effects are primarily attributed to bioactive compounds such as phyllanthin, hypophyllanthin, geraniin, corilagin, and quercetin. Commonly used TCM preparations, including aqueous decoctions and granule formulations of Yexiazhu, demonstrate therapeutic potential through modulation of oxidative stress, inflammatory signaling pathways, viral replication, and metabolic regulation. Despite strong experimental support from in vitro and in vivo models, clinical findings remain limited, heterogeneous, and occasionally inconsistent, particularly for hepatitis B and metabolic disorders.</div></div><div><h3>Discussion</h3><div>Collectively, <em>P. amarus</em> (Yexiazhu) represents a multifunctional medicinal herb with substantial experimental evidence supporting its traditional use in TCM and other medical systems. However, challenges related to species differentiation, phytochemical standardization, formulation variability, and limited high-quality clinical trials restrict its translation into modern evidence-based medicine. Future research should focus on standardized Chinese preparations, mechanistic validation, and rigorously designed clinical studies to clarify its therapeutic efficacy and safety.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100752"},"PeriodicalIF":0.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Echinacea-derived alkylamides as complementary immunomodulators: Potential for integration with synthetic immunosuppressive therapies 紫锥菊衍生的烷基酰胺作为互补免疫调节剂:与合成免疫抑制疗法整合的潜力
Pub Date : 2026-01-06 DOI: 10.1016/j.prmcm.2026.100754
Fatemeh Ahmadi , Ha Truong Nguyen , Zahra Ahmadi

Introduction

The escalating incidence of autoimmune and inflammatory disorders has intensified reliance on synthetic immunosuppressants, yet long-term safety issues and incomplete therapeutic responses persist. Concurrently, echinacea (紫锥菊, Zǐ Zhuī Jú) extracts rich in alkylamides show promising complementary immunoregulatory activity via cannabinoid receptor 2 (CB₂) engagement and toll-like receptor 4 (TLR4) modulation. In Traditional Chinese Medicine, echinacea is classified as a medicinal herb with a wide applications in treating wind-heat common cold, fever, cough, and sore throat.

Methods

This review integrates current pharmacodynamic and pharmacokinetic evidence on (i) corticosteroids, DMARDs, biologics, and JAK inhibitors, and (ii) echinacea-derived alkylamides and caffeic acid derivatives, to identify synergistic mechanisms relevant to integrative immunomodulation. We synthesised data from peer-reviewed articles retrieved through Web of Science, PubMed, and Scopus. Emphasis was placed on receptor-binding assays, in vivo efficacy models, and Phase I–III clinical trials.

Results

Synthetic agents chiefly exert single-target or pathway-restricted actions, e.g., glucocorticoid receptor transactivation, JAK–STAT blockade, yielding rapid symptom control but cumulative adverse events. By contrast, echinacea alkylamides demonstrate multi-target behaviour: nanomolar-affinity CB₂ activation dampens TNF-α and IL-6, whereas partial TLR4 antagonism re-balances Th1/Th2 cytokine bias, potentially complementing conventional immunosuppression. Integrating phytotherapeutics with conventional immunosuppressants may optimize efficacy–safety ratios through dose-sparing effects and enhanced therapeutic windows. However, heterogeneity in echinacea chemotypes demands rigorous standardization and head-to-head clinical trials evaluating combination therapies.

Discussion

The orthogonal engagement of CB₂ and TLR4 pathways by alkylamides complements the single-target mechanisms of corticosteroids, calcineurin inhibitors, and JAK inhibitors, enabling additive anti-inflammatory effects and potential dose-sparing strategies. This review positions echinacea as a rational adjuvant platform for next-generation complementary immunomodulation strategies within the framework of Traditional Chinese Medicine, supporting the development of personalized integrative approaches to immune disorders. Future research should exploit systems-biology-guided formulation to harness additive CB₂–TLR4 crosstalk in integrative treatment protocols.
自身免疫性疾病和炎症性疾病的发病率不断上升,对合成免疫抑制剂的依赖日益增强,但长期的安全性问题和不完全的治疗反应仍然存在。同时,富含烷基酰胺的紫锥菊提取物通过参与大麻素受体2 (CB₂)和toll样受体4 (TLR4)的调节,显示出有希望的互补免疫调节活性。在中医中,紫锥菊被归类为一种广泛应用于治疗风热性感冒、发烧、咳嗽和喉咙痛的草药。方法本综述整合了目前关于(i)皮质类固醇、DMARDs、生物制剂和JAK抑制剂的药效学和药代动力学证据,以及(ii)紫锥菊衍生的烷基酰胺和咖啡酸衍生物,以确定与综合免疫调节相关的协同机制。我们综合了通过Web of Science、PubMed和Scopus检索的同行评议文章的数据。重点放在受体结合试验、体内疗效模型和I-III期临床试验上。结果合成药物主要发挥单靶点或通路限制作用,如糖皮质激素受体转激活、JAK-STAT阻断等,可迅速控制症状,但不良事件累积。相比而言,紫锥花烷基酰胺表现出多靶点行为:纳米分子亲和的CB 2激活抑制TNF-α和IL-6,而部分TLR4拮抗重新平衡Th1/Th2细胞因子的偏性,潜在地补充了传统的免疫抑制。将植物疗法与传统免疫抑制剂相结合,可以通过剂量节约效应和增加治疗窗口来优化药效安全比。然而,紫锥菊化学型的异质性需要严格的标准化和头对头临床试验来评估联合治疗。烷基酰胺对CB₂和TLR4通路的正交作用补充了皮质类固醇、钙调磷酸酶抑制剂和JAK抑制剂的单靶点机制,实现了加性抗炎作用和潜在的剂量节约策略。本综述将紫锥菊定位为中医框架下下一代互补免疫调节策略的合理辅助平台,支持个性化免疫疾病综合治疗方法的发展。未来的研究应利用系统生物学指导配方,在综合治疗方案中利用添加剂CB₂-TLR4串扰。
{"title":"Echinacea-derived alkylamides as complementary immunomodulators: Potential for integration with synthetic immunosuppressive therapies","authors":"Fatemeh Ahmadi ,&nbsp;Ha Truong Nguyen ,&nbsp;Zahra Ahmadi","doi":"10.1016/j.prmcm.2026.100754","DOIUrl":"10.1016/j.prmcm.2026.100754","url":null,"abstract":"<div><h3>Introduction</h3><div>The escalating incidence of autoimmune and inflammatory disorders has intensified reliance on synthetic immunosuppressants, yet long-term safety issues and incomplete therapeutic responses persist. Concurrently, echinacea (紫锥菊, Zǐ Zhuī Jú) extracts rich in alkylamides show promising complementary immunoregulatory activity via cannabinoid receptor 2 (CB₂) engagement and toll-like receptor 4 (TLR4) modulation. In Traditional Chinese Medicine, echinacea is classified as a medicinal herb with a wide applications in treating wind-heat common cold, fever, cough, and sore throat.</div></div><div><h3>Methods</h3><div>This review integrates current pharmacodynamic and pharmacokinetic evidence on (i) corticosteroids, DMARDs, biologics, and JAK inhibitors, and (ii) echinacea-derived alkylamides and caffeic acid derivatives, to identify synergistic mechanisms relevant to integrative immunomodulation. We synthesised data from peer-reviewed articles retrieved through Web of Science, PubMed, and Scopus. Emphasis was placed on receptor-binding assays, in vivo efficacy models, and Phase I–III clinical trials.</div></div><div><h3>Results</h3><div>Synthetic agents chiefly exert single-target or pathway-restricted actions, e.g., glucocorticoid receptor transactivation, JAK–STAT blockade, yielding rapid symptom control but cumulative adverse events. By contrast, echinacea alkylamides demonstrate multi-target behaviour: nanomolar-affinity CB₂ activation dampens TNF-α and IL-6, whereas partial TLR4 antagonism re-balances Th1/Th2 cytokine bias, potentially complementing conventional immunosuppression. Integrating phytotherapeutics with conventional immunosuppressants may optimize efficacy–safety ratios through dose-sparing effects and enhanced therapeutic windows. However, heterogeneity in echinacea chemotypes demands rigorous standardization and head-to-head clinical trials evaluating combination therapies.</div></div><div><h3>Discussion</h3><div>The orthogonal engagement of CB₂ and TLR4 pathways by alkylamides complements the single-target mechanisms of corticosteroids, calcineurin inhibitors, and JAK inhibitors, enabling additive anti-inflammatory effects and potential dose-sparing strategies. This review positions echinacea as a rational adjuvant platform for next-generation complementary immunomodulation strategies within the framework of Traditional Chinese Medicine, supporting the development of personalized integrative approaches to immune disorders. Future research should exploit systems-biology-guided formulation to harness additive CB₂–TLR4 crosstalk in integrative treatment protocols.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100754"},"PeriodicalIF":0.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can Arthrospira (Spirulina) sp. be used to protect the kidneys and prevent hypertension? a systematic review and meta-analysis of preclinical studies 节肢螺旋藻可以保护肾脏和预防高血压吗?临床前研究的系统回顾和荟萃分析
Pub Date : 2026-01-04 DOI: 10.1016/j.prmcm.2026.100751
Gabrielly Hilário da Silva , Sabrina Swan Souza da Silva , Ana Lúcia Figueiredo Porto , Raquel Pedrosa Bezerra

Introduction

In Traditional Chinese Medicine (TCM), natural products such as Spirulina have been valued for centuries for their ability to regulate blood pressure and support organ function, including renal health. Arthrospira (Spirulina) sp., a blue-green cyanobacterium recognized by the United Nations as a "superfood of the future," is rich in phycocyanin, a pigment with emerging nephroprotective potential. This review evaluates the effects of Spirulina or phycocyanin, alone or in combination with other bioactives, on biomarkers of kidney function.

Methods

Systematic searches of databases like MEDLINE, Web of Science, LILACS, ScienceDirect, and CENTRAL between 2011 and 2024 are used to identify relevant studies for systematic reviews. The random-effect and inverse variance models were applied to verify data and perform meta-analysis. RoB tool for intervention studies (SYRCLE's RoB tool) and Cochrane Collaboration were used to assess quality and risk of bias.

Results

A total of 267 studies were identified, and after screening, 10 were selected for analysis. Despite high heterogeneity across studies, the overall effects were statistically significant. Risk of bias was low across all domains, indicating reliable and robust findings.

Discussion

The meta-analysis revealed that Arthrospira (Spirulina) and C-phycocyanin supplementation significantly improved biomarkers of kidney function, reducing serum creatinine, urea, uric acid, and urinary protein levels, as well as lowering systolic blood pressure in preclinical models. Despite consistent trends toward renoprotection and antihypertensive effects, high heterogeneity across studies highlights the need for further research to define optimal doses, treatment durations, and experimental conditions.
在传统中医(TCM)中,螺旋藻等天然产品因其调节血压和支持器官功能(包括肾脏健康)的能力而被重视了几个世纪。Arthrospira(螺旋藻)sp.是一种蓝绿色的蓝藻,被联合国认定为“未来的超级食物”,富含藻蓝蛋白,这是一种具有新兴肾保护潜力的色素。本综述评估了螺旋藻或藻蓝蛋白单独或与其他生物活性物质联合使用对肾脏功能生物标志物的影响。方法系统检索2011 - 2024年间的MEDLINE、Web of Science、LILACS、ScienceDirect、CENTRAL等数据库,筛选相关研究进行系统评价。采用随机效应和逆方差模型验证数据并进行meta分析。干预研究的RoB工具(sycle的RoB工具)和Cochrane协作用于评估质量和偏倚风险。结果共纳入研究267篇,经筛选筛选出10篇进行分析。尽管各研究的异质性很高,但总体效果在统计学上是显著的。所有领域的偏倚风险都很低,表明研究结果可靠而有力。荟萃分析显示,在临床前模型中,补充节螺旋藻和c -藻蓝蛋白可显著改善肾功能生物标志物,降低血清肌酐、尿素、尿酸和尿蛋白水平,并降低收缩压。尽管在肾保护和降压作用方面有一致的趋势,但研究之间的高度异质性表明需要进一步研究来确定最佳剂量、治疗持续时间和实验条件。
{"title":"Can Arthrospira (Spirulina) sp. be used to protect the kidneys and prevent hypertension? a systematic review and meta-analysis of preclinical studies","authors":"Gabrielly Hilário da Silva ,&nbsp;Sabrina Swan Souza da Silva ,&nbsp;Ana Lúcia Figueiredo Porto ,&nbsp;Raquel Pedrosa Bezerra","doi":"10.1016/j.prmcm.2026.100751","DOIUrl":"10.1016/j.prmcm.2026.100751","url":null,"abstract":"<div><h3>Introduction</h3><div>In Traditional Chinese Medicine (TCM), natural products such as <em>Spirulina</em> have been valued for centuries for their ability to regulate blood pressure and support organ function, including renal health. <em>Arthrospira</em> (<em>Spirulina</em>) sp., a blue-green cyanobacterium recognized by the United Nations as a \"superfood of the future,\" is rich in phycocyanin, a pigment with emerging nephroprotective potential. This review evaluates the effects of <em>Spirulina</em> or phycocyanin, alone or in combination with other bioactives, on biomarkers of kidney function.</div></div><div><h3>Methods</h3><div>Systematic searches of databases like MEDLINE, Web of Science, LILACS, ScienceDirect, and CENTRAL between 2011 and 2024 are used to identify relevant studies for systematic reviews. The random-effect and inverse variance models were applied to verify data and perform meta-analysis. RoB tool for intervention studies (SYRCLE's RoB tool) and Cochrane Collaboration were used to assess quality and risk of bias.</div></div><div><h3>Results</h3><div>A total of 267 studies were identified, and after screening, 10 were selected for analysis. Despite high heterogeneity across studies, the overall effects were statistically significant. Risk of bias was low across all domains, indicating reliable and robust findings.</div></div><div><h3>Discussion</h3><div>The meta-analysis revealed that <em>Arthrospira</em> (Spirulina) and C-phycocyanin supplementation significantly improved biomarkers of kidney function, reducing serum creatinine, urea, uric acid, and urinary protein levels, as well as lowering systolic blood pressure in preclinical models. Despite consistent trends toward renoprotection and antihypertensive effects, high heterogeneity across studies highlights the need for further research to define optimal doses, treatment durations, and experimental conditions.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100751"},"PeriodicalIF":0.0,"publicationDate":"2026-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulatory effect of Pien Tze Huang on the mTreg/mTh17 balance in mice with autoimmune hepatitis 片仔癀对自身免疫性肝炎小鼠mTreg/mTh17平衡的调节作用
Pub Date : 2026-01-02 DOI: 10.1016/j.prmcm.2026.100750
Linxin Zheng , Bugao Zhou , Miaohua Liu , Yi Xiong , Xin Zeng , Kaien Guo , Duanyong Liu

Objective

To investigate the therapeutic efficacy and underlying mechanisms of Pien Tze Huang (PTH) in a murine autoimmune hepatitis (AIH) model through assessment of memory regulatory T cells (mTreg)/memory T helper cell 17 (mTh17) cell equilibrium and glycolytic metabolism.

Methods

AIH was induced through intravenous concanavalin A (ConA) administration via tail vein injection with prophylactic PTH treatment over 10 days. Hepatic histopathological alterations were evaluated using H&E staining, while serum transaminase levels were quantified through biochemical analysis. ELISA was employed to determine immunoglobulin concentrations and hepatic tissue levels of interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 21 (IL-21), interleukin 10 (IL-10), interleukin 4 (IL-4), tumor necrosis factor α (TNF-α), interferon-gamma (IFN-γ), Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), glycolysis hexokinase 2 (HK2), pyruvate kinase (PK), glucose-6-phosphatase (G6pase), phosphoenolpyruvate carboxykinase (PEPCK), aldolase A (ALDOA), glucokinase (GCK), lactate dehydrogenase A (LDHA). Flow cytometric analysis was performed to quantify Treg, mTreg, Th17, and mTh17 cell populations. Protein expression of glucose transporter protein 1 (Glut1), glucose transporter protein 2 (Glut2), glucose transporter protein 3 (Glut3), glucose transporter protein 4 (Glut4), hypoxia-inducible factor-1α subunit (HIF-1α), signal transducer and activator of transcription 3 (STAT3), phosphorylated signal transducer and activator of transcription 3 (p-STAT3), T-cell transcription factor (T-bet), and retinoic acid receptor-related orphan receptor gamma (RORγt) was analyzed by Western blotting.

Results

Relative to the model group, PTH administration significantly ameliorated hepatocellular injury, as evidenced by reduced serum ALT and AST levels, decreased immunoglobulin concentrations, and attenuated hepatic pathological damage (p < 0.05 or p < 0.01). Furthermore, PTH treatment resulted in significant suppression of proinflammatory cytokine expression in murine hepatic tissue (p < 0.05 or p < 0.01). PTH treatment increased the proportions of Treg and mTreg cells while reducing Th17 and mTh17 cell populations (p < 0.05 or p < 0.01). Mechanistic investigations revealed that PTH significantly downregulated the expression of critical glycolytic enzymes and glycolysis-associated proteins in hepatic tissue of AIH model mice (p < 0.05 or p < 0.01).

Conclusions

PTH effectively attenuates ConA-induced AIH by modulating the balance of memory Treg/Th17 cells and glycolytic pathways.
目的通过对记忆调节性T细胞(mTreg)/记忆辅助性T细胞17 (mTh17)细胞平衡及糖酵解代谢的影响,探讨片仔黄(PTH)对小鼠自身免疫性肝炎(AIH)模型的治疗作用及机制。方法在预防PTH治疗10 d后,经尾静脉注射ConA诱导saih。采用H&;E染色评估肝脏组织病理学改变,同时通过生化分析量化血清转氨酶水平。ELISA法测定免疫球蛋白浓度及肝组织中白细胞介素1β (IL-1β)、白细胞介素6 (IL-6)、白细胞介素21 (IL-21)、白细胞介素10 (IL-10)、白细胞介素4 (IL-4)、肿瘤坏死因子α (TNF-α)、干扰素γ (IFN-γ)、免疫球蛋白G (IgG)、免疫球蛋白A (IgA)、免疫球蛋白M (IgM)、糖酵解己糖激酶2 (HK2)、丙酮酸激酶(PK)、葡萄糖-6-磷酸酶(G6pase)、磷酸烯醇丙酮酸羧激酶(PEPCK)、醛缩酶A (ALDOA)、葡萄糖激酶(GCK),乳酸脱氢酶(LDHA)。流式细胞分析定量Treg、mTreg、Th17和mTh17细胞群。Western blotting分析葡萄糖转运蛋白1 (Glut1)、葡萄糖转运蛋白2 (Glut2)、葡萄糖转运蛋白3 (Glut3)、葡萄糖转运蛋白4 (Glut4)、缺氧诱导因子1α亚基(HIF-1α)、转录信号转导和激活因子3 (STAT3)、磷酸化信号转导和激活因子3 (p-STAT3)、t细胞转录因子(T-bet)、视黄酸受体相关孤儿受体γ (rorγ γt)的蛋白表达。结果与模型组相比,PTH可显著改善肝细胞损伤,降低血清ALT和AST水平,降低免疫球蛋白浓度,减轻肝脏病理损伤(p <; 0.05或p <; 0.01)。此外,PTH治疗显著抑制小鼠肝组织中促炎细胞因子的表达(p <; 0.05或p <; 0.01)。PTH处理增加Treg和mTreg细胞比例,减少Th17和mTh17细胞数量(p <; 0.05或p <; 0.01)。机制研究显示PTH显著下调AIH模型小鼠肝组织中关键糖酵解酶和糖酵解相关蛋白的表达(p <; 0.05或p <; 0.01)。结论spth通过调节记忆Treg/Th17细胞和糖酵解通路的平衡,有效减弱cona诱导的AIH。
{"title":"Regulatory effect of Pien Tze Huang on the mTreg/mTh17 balance in mice with autoimmune hepatitis","authors":"Linxin Zheng ,&nbsp;Bugao Zhou ,&nbsp;Miaohua Liu ,&nbsp;Yi Xiong ,&nbsp;Xin Zeng ,&nbsp;Kaien Guo ,&nbsp;Duanyong Liu","doi":"10.1016/j.prmcm.2026.100750","DOIUrl":"10.1016/j.prmcm.2026.100750","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the therapeutic efficacy and underlying mechanisms of Pien Tze Huang (PTH) in a murine autoimmune hepatitis (AIH) model through assessment of memory regulatory T cells (mTreg)/memory T helper cell 17 (mTh17) cell equilibrium and glycolytic metabolism.</div></div><div><h3>Methods</h3><div>AIH was induced through intravenous concanavalin A (ConA) administration <em>via</em> tail vein injection with prophylactic PTH treatment over 10 days. Hepatic histopathological alterations were evaluated using H&amp;E staining, while serum transaminase levels were quantified through biochemical analysis. ELISA was employed to determine immunoglobulin concentrations and hepatic tissue levels of interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 21 (IL-21), interleukin 10 (IL-10), interleukin 4 (IL-4), tumor necrosis factor α (TNF-α), interferon-gamma (IFN-γ), Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), glycolysis hexokinase 2 (HK2), pyruvate kinase (PK), glucose-6-phosphatase (G6pase), phosphoenolpyruvate carboxykinase (PEPCK), aldolase A (ALDOA), glucokinase (GCK), lactate dehydrogenase A (LDHA). Flow cytometric analysis was performed to quantify Treg, mTreg, Th17, and mTh17 cell populations. Protein expression of glucose transporter protein 1 (Glut1), glucose transporter protein 2 (Glut2), glucose transporter protein 3 (Glut3), glucose transporter protein 4 (Glut4), hypoxia-inducible factor-1α subunit (HIF-1α), signal transducer and activator of transcription 3 (STAT3), phosphorylated signal transducer and activator of transcription 3 (p-STAT3), T-cell transcription factor (T-bet), and retinoic acid receptor-related orphan receptor gamma (RORγt) was analyzed by Western blotting.</div></div><div><h3>Results</h3><div>Relative to the model group, PTH administration significantly ameliorated hepatocellular injury, as evidenced by reduced serum ALT and AST levels, decreased immunoglobulin concentrations, and attenuated hepatic pathological damage (<em>p</em> &lt; 0.05 or <em>p</em> &lt; 0.01). Furthermore, PTH treatment resulted in significant suppression of proinflammatory cytokine expression in murine hepatic tissue (<em>p</em> &lt; 0.05 or <em>p</em> &lt; 0.01). PTH treatment increased the proportions of Treg and mTreg cells while reducing Th17 and mTh17 cell populations (<em>p</em> &lt; 0.05 or <em>p</em> &lt; 0.01). Mechanistic investigations revealed that PTH significantly downregulated the expression of critical glycolytic enzymes and glycolysis-associated proteins in hepatic tissue of AIH model mice (<em>p</em> &lt; 0.05 or <em>p</em> &lt; 0.01).</div></div><div><h3>Conclusions</h3><div>PTH effectively attenuates ConA-induced AIH by modulating the balance of memory Treg/Th17 cells and glycolytic pathways.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100750"},"PeriodicalIF":0.0,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100731"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147047731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100747"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147047743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"18 ","pages":"Article 100732"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147047754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmacological Research - Modern Chinese Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1